novel treatments

Research in Review

Leukemia Cancer Cells With TP53 Mutations Respond to Mild Chemotherapy

11/28/2016

JCP Editors

Patients with acute myeloid leukemia (AML) whose cells carry TP53 mutations may survive longer if they are treated with decitabine, according to a recent study in The New England Journal of...

...

11/28/2016

Journal of Clinical Pathways

Research in Review

Surgery Better Than Neoadjuvant Chemo for Epithelial Ovarian Cancer

11/23/2016

JCP Editors

Primary cytoreductive surgery (PCS) is better than neoadjuvant chemotherapy (NACT) for overall survival in women aged 70 years or younger with advanced-stage epithelial ovarian cancer (EOC), according to a recent...

...

11/23/2016

Journal of Clinical Pathways

Research in Review

TKI Drug Improves Survival in Metastatic Kidney Cancer

11/22/2016

JCP Editors

First-line therapy with cabozantinib was superior to standard of care sunitinib with respect to progression-free survival and objective response rate for patients with intermediate- or poor-risk metastatic renal cell...

...

11/22/2016

Journal of Clinical Pathways

Genetic Biomarkers Predict Treatment Outcomes for Patients With Breast Cancer

04/25/2016

JCP Editors

Results from a clinical trial presented at the 2016 American Association for Cancer Research Annual Meeting (April 16-20; New Orleans, LA) identified two genetic biomarkers capable of predicting which patients with...

...

04/25/2016

Journal of Clinical Pathways

TGFŒ≤ Pathway Inhibitor Improves Survival in Patients With Pancreatic Cancer

04/22/2016

JCP Editors

Galunisertib plus gemcitabine may improve overall survival and progression-free survival compared to gemcitabine alone in patients with pancreatic cancer, according to a study presented at the American Association...

...

04/22/2016

Journal of Clinical Pathways

Major Changes to NCCN Guidelines for Multiple Myeloma Announced

04/05/2016

JCP Editors

The National Comprehensive Cancer Network (NCCN) has announced three major changes to its guidelines for the treatment of multiple myeloma (MM) that broaden the population of patients eligible to start therapy,...

The...

04/05/2016

Journal of Clinical Pathways

Understanding New Treatments for Chronic Lymphocytic Leukemia

04/04/2016

JCP Editors

Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...

Recent...

04/04/2016

Journal of Clinical Pathways

Research in Review

Atezolizumab Safely Improves Survival for Patients Previously Treated for Non-Small Cell Lung Cancer

04/01/2016

JCP Editors

Atezolizumab may be a safe and effective option for patients with non-small cell lung cancer (NSCLC) who have progressed on post-platinum chemotherapy, according to results from a phase 2 randomized controlled...

...

04/01/2016

Journal of Clinical Pathways

Oncologists Call for New Metrics to Evaluate Effectiveness of Novel Treatments

03/17/2016

JCP Editors

At the 33rd Annual Miami Breast Cancer Conference (March 10-11, 2016; Miami Beach, FL), presenters called for new ways to evaluate the success of novel agents for the treatment of breast cancer. Although overall...

At the...

03/17/2016

Journal of Clinical Pathways

Conference Coverage

2015 American Society of Hematology Annual Meeting & Exposition

02/16/2016

JCP Editors

In April of 1958, the American Society of Hematology (ASH) was formed in Atlantic City, NJ, when 300 hematologists gathered to share their insights regarding blood diseases. Today, ASH is one of the world’s largest...

In...

02/16/2016

Journal of Clinical Pathways